Monocytes signatures in myeloproliferative neoplasms at diagnosis
Monocytes signatures in myeloproliferative neoplasms at diagnosis: The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
Study summary
Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of PV, ET, pre-myelofibrosis or primary myelofibrosis according to WHO 2022 criteria (including BOM for ET, premyelofibrosis and primary myelofibrosis)
* Patient who has not received treatment specific to hemopathy at the time of sampling
* Obtaining the signature of consent to participate in the study
* Patient having consented to be included in the "Malignant Hemopathy" collection of Angers University Hospital and in FIMBANK database
Exclusion Criteria:
* Person not affiliated to a social security scheme or beneficiary of such a scheme
* Patient with another hemopathy or another active cancer at the time of diagnosis
* Minor patient at diagnosis (\< 18 years old)
* Patient not capable or without agreement from the guardian or legal representative
Primary outcome measure(s)
WHO 2016 criteria for polycythemia vera, prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis — Day 0 Assessment of the monocytic signature against the WHO diagnosis (AUC will be determined)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.